EPR is attempting to provide an opportunity to save the life of a loved one when CPR procedures fail by inducing rapid profound hypothermia. Our proprietary techniques and products are planned to be used in serious trauma cases, such as auto accidents, shootings, sudden cardiac arrest, and other medical emergencies. The goal of EPR is to provide an emergency preservation period of approximately 3+ hours to buy critical time for transport to an emergency room or trauma center, and then immediate medical/surgical interventions and repairs, followed by delayed resuscitation.  

EPR can provide a period of tolerance to ischemia (that is, a lack of, or need for, oxygen), thereby preventing cell death even when there is no heartbeat, no breathing, and no brain function. By inducing a state in which no oxygen delivery is required for 3+ hours, EPR enables transport to a hospital followed by immediate surgical repairs and medical interventions. After essential surgical repairs, the patient is rewarmed and resuscitated. EPR-Technologies, Emergency Preservation and Resuscitation (EPR), rapid profound hypothermia, and the ongoing clinical trial at the R. Adams Cowley Shock Trauma Center at the University of Maryland are well known in the medical trauma and emergency medicine communities. Our company’s products are in final prototyping stages, and we await completion of the EPR clinical trial to put FDA-approved EPR products and training materials on the market. 

EPR-Technologies is dedicated to the memory and vision of Dr. Peter Safar, “the father of cardiopulmonary resuscitation” for pioneering the idea of rapid profound hypothermia to advance emergency medical resuscitation capabilities in order “to save hearts and brains too good to die”.

Too Many Lives Are Lost Annually Due to Failed CPR Attempts:  The numbers for CPR success remain limited, at about 12% for out-of-hospital use and 24%-40% in-hospital. For serious trauma leading to cardiac arrest, CPR only has a success rate of 5% at best. CPR is of particularly limited value to those victims whose cardiac arrest is a result of exsanguination (massive loss of blood) or sudden cardiac arrest (SCA). This is because the required surgery for quickly controlling massive blood loss cannot be performed in the field or even in trauma centers without sufficient time, so the victims generally die before they are transported to the nearest medical facility or before they receive definitive life-saving care. Similarly, the underlying causes leading to sudden cardiac arrest may not be easily reversed by CPR and defibrillation. Time is needed for a definitive intervention. Currently, if CPR doesn’t work immediately, there is no adequate alternative besides death. Our goal is to change that and provide another option for survival.

How EPR Saves Lives: We believe EPR represents a revolutionary opportunity for survival among victims when CPR fails following trauma and exsanguination cardiac arrest, sudden cardiac arrest (SCA) unresponsive to defibrillation, massive stroke, and other conditions requiring extended time for medical/surgical interventions. The procedure for inducing emergency preservation for up to 3+ hours requires cooling the patient within about 7 minutes after cardiopulmonary arrest or cessation of CPR. This rapid profound hyperthermia cooling is achieved by flushing the patient’s vasculature with a cold-flush solution at a temperature of approximately 1°C-2°C (33.8°F-35.6°F). The cold-flush solution is typically introduced through the patient’s major arteries, such as the aorta. The patient is then cooled to a tympanic membrane temperature of about 7°C-10°C (44.6°F-50°F) in less than 10-12 minutes. The EPR process isolates the heart, brain, and other vital organs to impose a state of clinical preservation for the critical period of approximately 3+ hours. The patient is then transported during this 3+ hour period so they can receive acute care at a hospital, including surgical repairs and medical interventions that they would not have had the opportunity to receive without EPR. The patient is ultimately resuscitated by the re-introduction of blood bank donor blood, using cardiopulmonary bypass (CPB), followed by rewarming. The patient ideally is rewarmed and resuscitated within 3+ hours or less from the time of initiation of emergency preservation and rapid profound hypothermia. The company plans to follow a business model somewhat similar to the introduction of Automatic External Defibrillators (AEDs) decades ago, when AEDs added one more chance to get the heart started when chest compressions and mouth-to-mouth breathing were inadequate. The use of AEDs quickly became the emergency standard of care, and we hope to replicate that success. We believe what makes EPR unique and revolutionary is the extended, 3+ hour period of emergency preservation for transport to a hospital for surgical repairs followed by delayed resuscitation. For the first time, resuscitation doesn’t require immediate success.

Pioneering an Industry to Meet Market Needs:  Approximately 2,000 people per day tragically die from traumatic exsanguination cardiac arrest or sudden cardiac arrest despite receiving CPR. And that breaks out to approximately 83 victims per hour: one victim of non-traumatic cardiac arrest every minute and one victim of trauma every three-to-four minutes. According to our industry research, EPR-Technologies has taken the leadership role in bringing EPR to market and developing a new standard of care that hasn't previously been available. The primary markets we plan to target include Level I Trauma Hospitals, Level II through Level V Hospitals, Emergency Rooms, ICUs, Patient Floors, Ambulances, and military combat casualty care needs. Emergency Medicine is already demonstrating trends towards investing in cooling equipment related to mild hypothermia treatments, which is cooling but dramatically different from rapid profound hypothermia in target temperature, equipment needs, and goals. Therapeutic Hypothermia and Temperature Management markets are increasing each year as these exciting new technologies are adopted. Meanwhile, the Automated External Defibrillator (AED) market is also rapidly expanding. We believe both of these trends demonstrate interest in EPR technology because it is a similar investment in life-saving equipment, disposables, and training for when CPR fails. 

Successful Trials, R&D Support, and Proprietary Technology:  For the past 15+ years, the Safar Center for Resuscitation Research at the University of Pittsburgh has successfully pursued large animal studies in which the use of rapid aortic cold flush to induce emergency preservation (EP) was followed by delayed resuscitation and full recoveries of the animals. These revolutionary studies have formed the basis of the emergency preservation and resuscitation (EPR) technology for our planned, patented product line of disposable EPR-Kits, EPR Cold Flush Solutions with additives, and EPR equipment for both emergency in-hospital and field use. An FDA-approved clinical trial is currently underway at Maryland Shock Trauma at the University of Maryland, Baltimore, MD. Maryland Shock Trauma is a nationally recognized Level I trauma center pioneering designs, facilities, and capabilities for rapid trauma care with a strong interest in advanced resuscitation techniques like EPR. The U.S. Army Medical Research and Development Command has always been a very strong supporter of innovative resuscitation techniques to save combat casualties suffering massive hemorrhage and cardiac arrest on the battlefield. The Army was the first to realize the importance of EPR and supplied early R&D funding as well as current support for the EPR clinical trial. 

Creating a New Emergency Medicine Standard of Care:  EPR-Technologies will continue to push the boundaries of emergency preservation and resuscitation in order to create a new lifesaving “Standard of Care'' in emergency medical responses. The Company has engaged in preliminary verbal discussions with medical device manufacturers interested in EPR’s specialized catheters and refrigerator/pump/monitoring systems for rapid profound hypothermia. No agreements with these potential manufacturers have been finalized as yet. In the future, we see this leading to a successful revenue stream, growing each year, with 2nd and 3rd generation products enabling EPR-Technologies to remain a research and revenue leader in the sub-niche of emergency preservation and delayed resuscitation. Besides the most important goal of saving lives, EPR-Technologies can benefit from being first in the medical emergency marketplace with a new innovative technique and customized products. We believe this presents an excellent opportunity to dominate the branding and market space, generate strong revenues, and create the potential for long-term growth. With promising technology, patents soon to be filed, and a clinical trial underway, we believe we are well on our way to achieving this vision. Join us as we seek to create a revolutionary new approach to resuscitation and help save lives that might otherwise be lost! 

EPR-Technologies has several key patents-in-preparation which will be completed and submitted in the US. and foreign countries using money from this raise. The initial six patents-in preparation include: (1) Specific EPR Induction Kit; (2) Novel Aortic Access Catheter; (3) Specifically Configured Hospital Refrigerator-Pump; (4) Unique Guided Transthoracic Catheter; (5) Ambulance Portable Refrigerator-Pump System; and (6) Oxygen Carrying Additive for EPR Induction Vascular Patency.

EPR-Technologies is also focused on bringing EPR capabilities to trauma victims at the point-of-injury by enabling paramedics to perform the procedures using semi-automated to fully automated equipment for inducing rapid profound hypothermia in the field.

Artificial Intelligence (AI) and Augmented Reality (AR) will be used within EPR induction procedures for data input including interpretation of catheter placement imaging, EPR induction data monitoring and analysis, decision support, protocol adjustments, and prediction of patient outcomes. Additionally, AI will be used to provide real-time objective decision support for electroencephalogram (EEG) analysis during EPR induction, with potential inclusion of EEG analysis or other key parameter conversion to sound as an AI-driven attention mechanism for emergency personnel. AI will be able to transform CPR-to-EPR decision support from the paramedic-patient pair interaction into a triple paramedic-patient-AI lifesaving endeavor.

Currently, EPR-Technologies has no competition for our efforts and/or clinical trials in rapid profound hypothermia to save trauma victims. The company anticipates having a 3-to-5-year window for marketing and growth before potential competitor entrance.

The key members of the EPR-Technologies' leadership team have been mentored by the renowned Dr. Peter Safar, considered the "Father of Cardiopulmonary Resuscitation (CPR)" and the pioneer to develop rapid profound hypothermia.

EPR-Technologies is a biomedical company seeking to lead advances in emergency medicine to save lives in serious trauma cases and sudden cardiac arrest when cardiopulmonary resuscitation (CPR) fails. Serious trauma is one of the leading causes of death in people under age 45. We believe the potential market is huge and EPR is positioned to capture a very significant share of the rapid market growth following Food and Drug Administration (FDA) final approval of ongoing Emergency Preservation and Resuscitation (EPR) clinical trials. EPR can be used to induce rapid profound hypothermia, a state in which no oxygen delivery is required for 3+ hours, buying life-saving time for transport to a hospital followed by immediate surgical repairs and medical interventions. We believe EPR is the next revolutionary resuscitation step in saving the lives of loved ones too precious to be lost. EPR is in the pre-revenue stage of development and the Company's products are not available to the general public.

INVEST NOW and SAVE LIVES

ADDITIONAL EPR RESOURCES

Follow us as we Change the World

EPR-Technology NEWS

EPR-Technologies Articles 

EPR Clinical Trials

Investor Opportunity 12X Return 

Select a Date & Time - Calendly 

EPR Facebook Group

EPR-TEDx-University-of-Maryland

FAQ's EPR-Technologies (epr-technology.com)